Estonia's human pharmaceuticals market grew by 5% in the first quarter of 2010 to Eek738 million ($57.8 million) in wholesale prices compared with the same period last year, but was10% lower than the fourth quarter of 2009.
Estonia's human pharmaceuticals market grew by 5% in the first quarter of 2010 to Eek738 million ($57.8 million) in wholesale prices compared with the same period last year, but was10% lower than the fourth quarter of 2009.
Sales to retail pharmacies stood at Eek554 million (Eek634 million in the fourth quarter of 2009) and those to hospital...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
